RxDoctor Payments Data

Aliya Rathore, MD

Family Medicine · Wesley Chapel, FLNPI 1093757262

Payments from drug & device makers

$3,600in general payments, 2019–2025

Across 159 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$906
  • GSK$398
  • AstraZeneca$304
  • Lilly USA, LLC$288
  • Boehringer Ingelheim$256
  • Johnson & Johnson$243
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$501%
  • Food & beverage$3,55099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,600 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,936
Medicare patients
43
Services billed
206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$66,460
FarxigaDapagliflozin Propanediol13$20,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,733
Tresiba Flextouch U-200Insulin Degludec17$17,482
OzempicSemaglutide14$12,714
Atorvastatin Calcium281$2,101
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,078
Gabapentin38$1,748
Levothyroxine Sodium141$1,521
Losartan Potassium192$1,447
Carvedilol76$947
Famotidine49$834
SynthroidLevothyroxine Sodium13$797
Omeprazole67$797
Pantoprazole Sodium47$781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$256$66,46039 claims
AstraZenecaFarxiga$304$20,42313 claims
GSKTrelegy Ellipta$398$18,73318 claims
Novo NordiskOzempic$906$12,71414 claims
AbbVieSynthroid$51$79713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →